



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 6200

SERIAL NUMBER	FILING or 371(c) DATE RULE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/521,929	08/05/2005	514	1614	ON/4-32586A

APPLICANTS
 Akira Ohtsuru, Nagasaki, JAPAN;
 Alexej Podtcheko, Nagasaki, JAPAN;
 Satoshi Tsuda, Nagasaki, JAPAN;
 Shunichi Yamashita, Nagasaki, JAPAN;

**** CONTINUING DATA *******
 This application is a 371 of PCT/IB03/01985 05/23/2003
 which claims benefit of 60/398,410 07/24/2002
 and claims benefit of 60/454,557 03/14/2003

**** FOREIGN APPLICATIONS *******

**** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ****

Foreign Priority claimed <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<input type="checkbox"/> Met after Allowance	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
35 USC 119(a-d) conditions met <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Initials	JAPAN	0	8	3
Verified and Acknowledged	/LESLIE A ROYDS/ Examiner's Signature				

ADDRESS
 NOVARTIS
 CORPORATE INTELLECTUAL PROPERTY
 ONE HEALTH PLAZA 104/3
 EAST HANOVER, NJ 07936-1080
 UNITED STATES

TITLE
 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl]pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer

FILING FEE RECEIVED 1030	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit